Division of Bristol-Myers Squibb Co.
Latest From Medarex Inc.
PD-1 discoverer and the Japanese co-developer of Opdivo remain locked in simmering dispute over patent royalties, with a revised one-off settlement or legal action emerging as possible near-term options.
The mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes. Celgene’s partners, and their investors, are concerned about the ramifications.
The $74bn mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes.
Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Bristol-Myers Squibb Co.
- Senior Management
Howard H Pien, Pres. & CEO
Christian S Schade , SVP, Fin. & Admin. & CFO
Ronald A Pepin, PhD, SVP, Bus. Dev.
- Contact Info
Phone: (609) 430-2880
707 State Rd.
P.O. Box 930 Princeton, NJ 08540-1437
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.